Detalhe da pesquisa
1.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Invest New Drugs
; 40(1): 68-80, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34417912
2.
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Invest New Drugs
; 39(3): 803-811, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33462752
3.
Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy.
Br J Clin Pharmacol
; 85(7): 1495-1506, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30866056
4.
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Invest New Drugs
; 36(5): 848-859, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29349598
5.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Lancet Oncol
; 16(8): 949-56, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26179200
6.
Effects of high-density lipoprotein elevation with cholesteryl ester transfer protein inhibition on insulin secretion.
Circ Res
; 113(2): 167-75, 2013 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-23676183
7.
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Cancer Chemother Pharmacol
; 91(3): 239-246, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36884068
8.
Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
Cancer Chemother Pharmacol
; 89(3): 363-372, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35118559
9.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
J Immunother Cancer
; 10(5)2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35577503
10.
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
Neuro Oncol
; 24(10): 1776-1789, 2022 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35395680
11.
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
Cancer Chemother Pharmacol
; 88(6): 997-1007, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34536094
12.
Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making.
Eur J Drug Metab Pharmacokinet
; 46(6): 779-791, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34495458
13.
Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Eur J Clin Pharmacol
; 66(8): 775-83, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20521033
14.
Therapeutically-induced stable disease in oncology early clinical trials.
PLoS One
; 15(5): e0233882, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32470048
15.
Physiologically Based Absorption Modelling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Entrectinib.
AAPS J
; 22(4): 78, 2020 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32458089
16.
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Clin Pharmacol Ther
; 108(3): 616-624, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575160
17.
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33097612
18.
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.
Cancer Chemother Pharmacol
; 82(3): 395-406, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29915982
19.
Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy.
Mol Cancer Ther
; 17(7): 1464-1474, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29654069
20.
Accelerating drug development by efficiently using emerging PK/PD data from an adaptable entry-into-human trial: example of lumretuzumab.
Cancer Chemother Pharmacol
; 79(6): 1239-1247, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28497320